Profile of:

Mitsumasa Kishimoto

Full name: Mitsumasa Kishimoto

Current country: Japan

Membership level: Full

Type of membership: Member

Number of publications: 41

Axial Spondyloarthritis in Japan (2022)

Clinical characteristics of patients with spondyloarthritis and inflammatory bowel disease versus inflammatory bowel disease-related arthritis (2022)

Patient perceptions of psoriatic disease in Japan: Results from the Japanese subgroup of the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey (2022)

Pro and contra: is synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) a spondyloarthritis variant? (2022)

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension (2022)

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial (2022)

Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study (2022)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis (2022)

Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study (2022)

Management of Psoriatic Arthritis in Patients With Comorbidities: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations (2022)

A Nationwide Questionnaire Survey on the Prevalence of Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis in Japan (2021)

SAPHO Syndrome and Pustulotic Arthro-Osteitis (PAO) (2021)

Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study (2021)

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study (2021)

Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1 (2021)

Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: results of the cross-sectional ASAS-COMOSPA study (2021)

Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension (2021)

Response to: ‘Correspondence on ‘Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial” by Zhao and Huang (2021)

Pustular Psoriasis and Associated Musculoskeletal Disorders (2021)

Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial (2021)

Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis (2021)

Clinical features of psoriatic arthritis (2021)

Pustular Psoriasis and Associated Musculoskeletal Disorders (2021)

Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study (2021)

The Diagnosis and Treatment of Adult Patients with SAPHO Syndrome: Controversies Revealed in a Multidisciplinary International Survey of Physicians (2021)

Unveiling axial involvement in psoriatic arthritis: An ancillary analysis of the ASAS-perSpA study (2021)

Reactive arthritis after COVID-19 infection (2020)

Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J) (2020)

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial (2019)

2018 APLAR axial spondyloarthritis treatment recommendations (2019)

Clinical Characteristics of Patients with Spondyloarthritis in Japan in Comparison with Other Regions of the World (2019)

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1) (2018)

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1) (2018)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1 (2017)

Nail findings in patients with psoriatic arthritis: A cross-sectional study with special reference to transverse grooves (2017)

Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study (2016)

Prevalence and Clinical Characteristics of Psoriatic Arthritis in Japan (2015)

Magnetic resonance angiography in psoriatic arthritis of the hand (2012)

Clinical Images: iliopsoas bursa rupture mimicking psoas muscle abscess (2010)

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis (2006)

Syphilis mimicking Reiter’s syndrome in an HIV-positive patient (2006)